ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ABILIFY INJECTION
Mood disorders
Psychosis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ABILIFY INJECTION Rx

Generic Name and Formulations:
Aripiprazole 7.5mg/mL; soln for IM use only.

Company:
Otsuka America Pharmaceutical, Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Product Resources »
  • Product Information
  • Coupons, Samples & Vouchers
  • Patient Education and Assistance

Indications for ABILIFY INJECTION:

Treatment of agitation associated with acute manic or mixed episodes in bipolar disorder.

Adult Dose for ABILIFY INJECTION:

9.75mg IM, if 2nd dose is needed, may repeat after 2 hours; max 30mg/day. Switch to oral form as soon as possible. Reduce aripiprazole dose by at least ½ with CYP3A4 inhibitors or CYP2D6 inhibitors. Double aripiprazole dose (max 30mg/day) with CYP3A4 inducers. Adjust dose to normal range when these drugs are withdrawn. Other dose adjustments: see full labeling.

Children's Dose for ABILIFY INJECTION:

Not recommended.

See Also:

ABILIFY

ABILIFY DISCMELT

ABILIFY ORAL SOLUTION

Warnings/Precautions:

Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults; monitor closely for worsening or unusual changes in behavior in all patients. Cardio- or cerebrovascular disease. Risk of hypotension, aspiration pneumonia, seizures, or diabetes (do baseline fasting blood sugar). Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Exposure to extreme heat. Dehydration. Reevaluate periodically. Monitor for hyperglycemia, dyslipidemia, weight gain. Exclude neuroleptic malignant syndrome if fever occurs. Suicidal tendencies. Write ℞ for smallest practical amount. Labor & delivery. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Avoid alcohol. Caution with other centrally-acting drugs. Potentiates antihypertensives. Levels may be reduced by CYP3A4 inducers (eg, carbamazepine). Levels may be increased by CYP3A4 inhibitors (eg, ketoconazole) or CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Caution with drugs that interfere with temperature regulation (eg, anticholinergics).

Adverse Reactions:

Headache, anxiety, insomnia, constipation, vomiting, somnolence, fatigue, sedation, restlessness, akathisia, orthostatic hypotension, asthenia, blurred vision, tremor, pyrexia, salivary hypersecretion, neuroleptic malignant syndrome, tardive dyskinesia, weight gain, dyslipidemia, others. Inj: local reactions.

How Supplied:

Tabs 2mg—30; 5mg, 10mg, 15mg, 20mg, 30mg—30, 100; Oral soln (w. dosing cup)—150mL; Discmelt—30; Single use vials—1

Indications for ABILIFY INJECTION:

Treatment of agitation associated with schizophrenia.

Adult Dose for ABILIFY INJECTION:

9.75mg IM, if 2nd dose is needed, may repeat after 2 hours; max 30mg/day. Switch to oral form as soon as possible. Reduce aripiprazole dose by at least ½ with CYP3A4 inhibitors or CYP2D6 inhibitors. Double aripiprazole dose (max 30mg/day) with CYP3A4 inducers. Adjust dose to normal range when these drugs are withdrawn. Other dose adjustments: see full labeling.

Children's Dose for ABILIFY INJECTION:

Not recommended.

See Also:

ABILIFY

ABILIFY DISCMELT

ABILIFY MAINTENA

ABILIFY ORAL SOLUTION

Warnings/Precautions:

Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults; monitor closely for worsening or unusual changes in behavior in all patients. Cardio- or cerebrovascular disease. Risk of hypotension, aspiration pneumonia, seizures, or diabetes (do baseline fasting blood sugar). Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Exposure to extreme heat. Dehydration. Reevaluate periodically. Monitor for hyperglycemia, dyslipidemia, weight gain. Exclude neuroleptic malignant syndrome if fever occurs. Suicidal tendencies. Write ℞ for smallest practical amount. Labor & delivery. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Avoid alcohol. Caution with other centrally-acting drugs. Potentiates antihypertensives. Levels may be reduced by CYP3A4 inducers (eg, carbamazepine). Levels may be increased by CYP3A4 inhibitors (eg, ketoconazole) or CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Caution with drugs that interfere with temperature regulation (eg, anticholinergics).

Adverse Reactions:

Headache, anxiety, insomnia, constipation, vomiting, somnolence, fatigue, sedation, restlessness, akathisia, orthostatic hypotension, asthenia, blurred vision, tremor, pyrexia, salivary hypersecretion, neuroleptic malignant syndrome, tardive dyskinesia, weight gain, dyslipidemia, others. Inj: local reactions.

How Supplied:

Tabs 2mg—30; 5mg, 10mg, 15mg, 20mg, 30mg—30, 100; Oral soln (w. dosing cup)—150mL; Discmelt—30; Maintena Kit—1 (w. supplies); Single use vials—1

Sign Up for Free e-newsletters